Form 8-K - Current report:
SEC Accession No. 0001213900-25-067345
Filing Date
2025-07-24
Accepted
2025-07-24 16:15:43
Documents
14
Period of Report
2025-07-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0250005-8k_abpro.htm   iXBRL 8-K 31299
2 CONSULTING AGREEMENT DATED JULY 20, 2025 ea025000501ex10-1_abpro.htm EX-10.1 23241
  Complete submission text file 0001213900-25-067345.txt   274204

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE abp-20250720.xsd EX-101.SCH 3887
4 XBRL DEFINITION FILE abp-20250720_def.xml EX-101.DEF 26777
5 XBRL LABEL FILE abp-20250720_lab.xml EX-101.LAB 36995
6 XBRL PRESENTATION FILE abp-20250720_pre.xml EX-101.PRE 25401
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0250005-8k_abpro_htm.xml XML 6001
Mailing Address 6 ST JOHNS LANE, FLOOR 5 NEW YORK NY 10013
Business Address 6 ST JOHNS LANE, FLOOR 5 NEW YORK NY 10013 248-890-7200
Abpro Holdings, Inc. (Filer) CIK: 0001893219 (see all company filings)

EIN.: 871013956 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41224 | Film No.: 251147063
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)